JKE-1674

$140$1,150

Products Details

Product Description

– JKE-1674 is an orally active glutathione peroxidase 4 (GPX4) inhibitor and an active metabolite of GPX4 inhibitor ML-210. JKE-1674, an analog of ML-210 in which the nitroisoxazole ring is replaced with an α-nitroketoxime. JKE-1674 can convert into a nitrile oxide JKE-1777. JKE-1674 kills LOX-IMVI cells in a manner that is equipotent to ML-210 and is completely rescued by ferroptosis inhibitors[1][2][3].

Web ID

– HY-138153

Storage Temperature

– 4°C (Powder, protect from light)

Shipping

– Room Temperature

Applications

– Cancer-programmed cell death

Molecular Formula

– C20H20Cl2N4O4

References

– [1]Eaton JK, et al. Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles. Nat Chem Biol. 2020;16(5):497-506.|[2]Kathman SG, et al. A masked zinger to block GPX4. Nat Chem Biol. 2020;16(5):482-483.|[3]Viswanathan VS, et al. Unraveling Masked GPX4 Inhibitors. Nat. Chem. Biol. 2020, 16, 497–506.

CAS Number

– 2421119-60-8

Molecular Weight

– 451.30

Compound Purity

– 98.30

SMILES

– O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C3=CC=C(Cl)C=C3)CC1)/C(C[N+]([O-])=O)=N/O

Clinical Information

– No Development Reported

Research Area

– Cancer

Solubility

– DMSO : 100 mg/mL (ultrasonic)|Ethanol : ≥ 50 mg/mL

Target

– Ferroptosis;Glutathione Peroxidase

Pathway

– Apoptosis;Metabolic Enzyme/Protease

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=